Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.
Randomized, dose-escalation study of the p38a MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2013 Apr; 27(4):977-80.